- Home
- SST vs CMMB Comparison
SST vs CMMB Comparison
Compare SST & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SST | CMMB |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | Israel |
| Employees | 250 | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9M | 11.2M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | SST | CMMB |
|---|---|---|
| Price | $3.65 | $1.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $10.00 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 3.6M | 34.4K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $36.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $0.87 |
| 52 Week High | $11.30 | $3.86 |
Technical Indicators
Market Signals| Indicator | SST | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 57.40 | 35.62 |
| Support Level | $3.09 | $1.41 |
| Resistance Level | $4.61 | $1.64 |
| Average True Range (ATR) | 0.61 | 0.10 |
| MACD | 0.15 | -0.02 |
| Stochastic Oscillator | 55.71 | 9.37 |
Price Performance
Historical ComparisonAbout SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It operate several flagship brands across multiple consumer verticals, including shopping, travel and search, and a customer acquisition and marketing platform powered by Artificial Intelligence and machine learning. The company's segment includes Marketing and Products. It generates maximum revenue from the Marketing segment. Geographically, it operates in United States and Other countries.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.